ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5. ...

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma ...

Arvinas to present preclinical data on ARV-393, a BCL6 degrader, at the EHA meeting in Milan, June 2025. Quiver AI Summary Arvinas, Inc. announced that it will present new preclinical data on its ...

ARV-393 shows promising antitumor effects in combination with standard therapies for non-Hodgkin lymphoma, warranting further investigation. Quiver AI Summary Arvinas, Inc. announced promising ...

Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting Chimera/PROTAC B-cell lymphoma 6 protein (BCL6) degrader, called ARV-393, at the ...